Ovid Therapeutics Correlations
OVID Stock | USD 0.43 0.05 10.42% |
The current 90-days correlation between Ovid Therapeutics and CytomX Therapeutics is 0.29 (i.e., Modest diversification). The correlation of Ovid Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Ovid Therapeutics Correlation With Market
Average diversification
The correlation between Ovid Therapeutics and DJI is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ovid Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Ovid |
Moving together with Ovid Stock
0.87 | EYEN | Eyenovia | PairCorr |
0.64 | MOLN | Molecular Partners | PairCorr |
0.67 | SNDL | SNDL Inc | PairCorr |
0.91 | CLDX | Celldex Therapeutics | PairCorr |
0.93 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.73 | CRVS | Corvus Pharmaceuticals | PairCorr |
0.67 | GKOS | Glaukos Corp | PairCorr |
0.65 | LIVN | LivaNova PLC | PairCorr |
0.66 | MDAI | Spectral AI | PairCorr |
0.9 | MODD | Modular Medical | PairCorr |
0.86 | APYX | Apyx Medical | PairCorr |
0.89 | SGHT | Sight Sciences | PairCorr |
0.91 | SRDX | SurModics | PairCorr |
0.77 | CNMD | CONMED | PairCorr |
Moving against Ovid Stock
0.88 | FNA | Paragon 28 | PairCorr |
0.82 | CPIX | Cumberland Pharmaceuticals | PairCorr |
0.8 | CMRX | Chimerix | PairCorr |
0.35 | OPT | Opthea | PairCorr |
0.91 | NVRO | Nevro Corp | PairCorr |
0.84 | LUCD | Lucid Diagnostics | PairCorr |
0.75 | NYXH | Nyxoah | PairCorr |
0.66 | INMD | InMode | PairCorr |
0.61 | LUNG | Pulmonx Corp | PairCorr |
0.47 | KIDS | Orthopediatrics Corp | PairCorr |
0.87 | BRK-A | Berkshire Hathaway | PairCorr |
0.87 | BRK-B | Berkshire Hathaway | PairCorr |
0.79 | FWEDF | Fireweed Zinc | PairCorr |
0.79 | TOI | Oncology Institute Earnings Call This Week | PairCorr |
0.65 | NHNCF | NAVER Corp | PairCorr |
0.61 | TRGGF | Tarachi Gold Corp | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ovid Stock performing well and Ovid Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ovid Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CTMX | 3.60 | (0.53) | 0.00 | (0.32) | 0.00 | 7.32 | 17.13 | |||
SPRO | 2.59 | (0.31) | 0.00 | (0.73) | 0.00 | 5.13 | 21.98 | |||
NLTX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
TIL | 5.56 | 0.11 | 0.00 | (0.03) | 0.00 | 13.25 | 34.30 | |||
NXTC | 3.52 | (0.75) | 0.00 | (0.48) | 0.00 | 6.49 | 21.57 | |||
ASMB | 3.04 | (0.35) | 0.00 | (0.37) | 0.00 | 6.63 | 24.82 | |||
ACHL | 1.59 | 0.69 | 0.51 | 1.23 | 0.49 | 3.47 | 22.77 | |||
NUVB | 3.32 | (0.34) | 0.00 | (0.59) | 0.00 | 6.88 | 28.03 | |||
CNTB | 3.51 | (0.29) | 0.00 | (0.33) | 0.00 | 7.59 | 29.84 |
Ovid Therapeutics Corporate Management
Meg Alexander | Chief Officer | Profile | |
Claude MD | Head RD | Profile | |
SPHR SHRMSCP | VP Facilities | Profile | |
Jason MBA | Chief Officer | Profile | |
Lora Pike | Senior Relations | Profile | |
Garret Bonney | Investor Officer | Profile |